secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-12-05T23:59:59+00:00
Accession:  0001193125-22-298002
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD licenses products to Mayne Pharma for ~$153.1M upfront plus royalties and milestones
--------------------------------------------------------------------------------

- Upfront cash payment of $140.0M plus ~$13.1M for net working capital at closing.
- Min annual royalty $3M/year for 12 years (cumulative ~$42.6M); plus sales milestones up to $30M.
- Royalty rate 8% on first $80M annual net sales, 7.5% above $80M over 20 years.
- Proceeds will repay Sixth Street debt and redeem preferred equity; TXMD to become a royalty company.
- Closing expected end of 2022, subject to HSR waiting period; no financing condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312522298002/0001193125-22-298002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-298002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer